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Abstract
Backgrounds: Although neurofibrillary tangles (NFTs) mainly accumulate in the medial temporal lobe with human
aging, only a few imaging studies have investigated correlations between NFT accumulation and gray matter (GM)
volume in cognitively normal older adults. Here, we investigated the correlations between 18F-THK5351
accumulation and GM volume at the voxel level.
Material and methods: We recruited 47 amyloid-negative, cognitively normal, older adults (65.0 ± 7.9 years, 26
women), who underwent structural magnetic resonance imaging, 11C-Pittsburgh compound-B and 18F-THK5351 PET
scans, and neuropsychological assessment. The magnetic resonance and 18F-THK5351 PET images were spatially
normalized using Statistical Parametric Mapping 12. Voxel-wise correlations between 18F-THK5351 accumulation and
GM volume were evaluated using the Biological Parametric Mapping toolbox.
Results: A significant negative correlation (p < 0.001) between 18F-THK5351 accumulation and GM volume was
detected in the bilateral medial temporal lobes.
Conclusions: Voxel-wise correlation analysis revealed a significant negative correlation between 18F-THK5351
accumulation and GM volume in the medial temporal lobe in individuals without amyloid-β deposits. These results
may contribute to a better understanding of the pathophysiology of primary age-related tauopathy in human
aging.
Keywords: Cognitively normal older adult, Medial temporal lobe, 18F-THK5351 PET, Gray matter volume, Primary
age-related tauopathy
Introduction
Neuropathological studies have revealed that neurofibril-
lary tangles (NFTs) mainly accumulate in the medial
temporal lobe (MTL) with human aging. Although neu-
rodegeneration is also a feature of aging, in addition to
tau pathology, only a few imaging studies have specific-
ally investigated correlations between tau accumulation
and brain volume [1, 2]. Although 18F-THK5351 was
originally developed as a tau-specific tracer, recent
studies have clarified the off-target binding to
monoamine oxidase B (MAO-B) [3]. Because 18F-
THK5351 accumulation reflects the combination of
astrogliosis, in addition to tau pathology, it is now con-
sidered the promising biomarker for detecting neuroin-
flammation [4]. Previously, using region of interest
(ROI) analysis, we did not detect significant negative
correlations between 18F-THK5351 accumulation and
gray matter (GM) volume [5]. In this study, we aimed to
re-examine the correlations between 18F-THK5351 accu-
mulation and GM volume at the voxel level.
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Materials and methods
Participants
We recruited 47 cognitively normal older adults from the
Brain Mapping by Integrated Neurotechnologies for
Disease Studies (Brain/MINDS) project (grant number
18dm0207017h0005), who underwent structural magnetic
resonance imaging and 11C-Pittsburgh compound-B (PiB)
and 18F-THK5351 PET scans. All participants underwent
cognitive testing that included the Mini-Mental State
Examination (MMSE), global Clinical Dementia Rating
Scale (CDR), and Wechsler Memory Scale-Revised Logical
Memory II (WMSR LM-II). The inclusion criteria were
the following: visually negative PiB PET results, a global
CDR of 0, an MMSE ≥ 26, and performance within educa-
tion-adjusted norms for WMSR LM-II, absence of neuro-
logical or psychiatric disorders, and no medications that
affect cognition.
Data acquisition
All participants underwent 3D T1-weighted scans with a
3-T magnetic resonance imaging system (Verio; Siemens,
Erlangen, Germany). PET scans were acquired using a
Siemens/Biograph TruePoint16 Scanner (3D acquisition
mode; 81 image planes; 16.2-cm axial field of view;
4.2-mm transaxial resolution; 4.7-mm axial resolution;
2-mm slice interval). For 11C-PiB imaging, partici-
pants were injected with 555 ± 185MBq of PiB prior
to imaging and imaging was performed for a 20-min PET
acquisition, 50 ± 5min post-injection. For 18F-THK5351
imaging, participants were injected with 185 ± 37MBq of
THK5351 prior to imaging and imaging was performed
for a 20-min PET acquisition, 40 ± 5min post-injection.
PET/CT data were reconstructed using an iterative 3D or-
dered subset expectation maximization reconstruction
algorithm.
Data preprocessing
The partial volume corrected 18F-THK5351 PET images
using PETPVE12 toolbox [6] were normalized using
SPM12 (Statistical Parametric Mapping 12; Wellcome
Department of Cognitive Neurology, London, England).
Each participant’s 18F-THK5351 PET image was
coregistered to its T1-weighted image and normalized
with Diffeomorphic Anatomical Registration Through
Exponentiated Lie Algebra. A transformation matrix was
applied to each 18F-THK5351 PET image, which had
been coregistered to the T1-weighted images. After
spatial normalization, standardized uptake value ratios
(SUVRs) for 18F-THK5351 PET images were calculated
using the individual’s positive mean uptake value of
cerebellar GM as the reference region. Finally, each PET
image was smoothed by an 8-mm full width at half max-
imum (FWHM) Gaussian kernel. The GM images
segmented using SPM12 were also normalized and
smoothed using an 8-mm FWHM Gaussian kernel.
Statistical analyses
The Biological Parametric Mapping (BPM) toolbox
allows voxel-level comparisons across imaging modal-
ities based on the general linear model to perform
regressions [7]. Using the BPM toolbox, we evaluated
the direct correlations between 18F-THK5351 accumula-
tion and GM volume at the voxel level. Results were
considered significant at p < 0.001 with an extent thresh-
old of 30 voxels (uncorrected for multiple comparisons).
Results
The participants’ demographics are shown in Table 1.
Mean age ± standard deviation was 65.0 ± 7.9 years and
mean cognitive scores were 29.3 ± 1.1 for MMSE and
13.4 ± 2.9 for WMSR LM-II.
Localized 18F-THK5351 accumulation was detected
mainly in the basal ganglia, thalamus, MTL but slightly
extended into the inferior temporal lobe, insula, poster-
ior cingulate cortex/precuneus, and basal frontal lobe
(Fig. 1). We found a significant negative correlation
between 18F-THK5351 accumulation and GM volume in
the bilateral MTL, right parahippocampal gyrus (cluster
size, 40 voxels; Z-score, 4.68; MNI coordinate [x, y, z],
[32, − 18, − 18]), right hippocampus, left parahippocam-
pal gyrus (cluster size, 56 voxels; Z-score, 4.68; MNI
coordinate [x, y, z], [− 26, − 8, − 22]), and left amygdala
(Fig. 2).
Discussion
This is the first study to investigate direct correlations
between 18F-THK5351 accumulation and GM volume at
the voxel level using BPM in cognitively normal older
adults. We detected significant correlations between an
increased 18F-THK5351 accumulation and reduced GM
volume in the MTL. Our findings may contribute to a
better understanding of the pathophysiology of human
aging.
We found significant 18F-THK5351 accumulation
mainly in the basal ganglia, thalamus, MTL slightly
extending into the inferior temporal lobe, insula,
Table 1 Participants’ demographics
Cognitively normal
older adults
No. (% women) 47 (26)
Age, year 65.0 ± 7.9 [50–86]
Education, year 14.3 ± 2.4 [9–22]
MMSE 29.3 ± 1.1 [26–30]
WMSR LM-II 13.4 ± 2.9 [8–19]
Values are mean ± standard deviation [range]. MMSE Mini-Mental State
Examination, WMSR LM-II Wechsler Memory Scale-Revised Logical Memory II
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Fig. 1 Mean SUVR images of 18F-THK5351 in cognitively normal older adults. Localized 18F-THK5351 accumulation was mainly evident in the basal
ganglia, thalamus, and medial temporal lobe, which slightly extended to the inferior temporal lobe, insula, posterior cingulate gyrus/precuneus,
and basal frontal lobe. SUVR, standardized uptake value ratio
Fig. 2 Voxel-wise correlations between 18F-THK5351 accumulation and gray matter volume in normal older adults. Significant negative correlations
between 18F-THK5351 accumulation and gray matter volume were detected in the bilateral medial temporal lobes (voxel threshold of p < 0.001 with a
30-voxel extent threshold). A anterior, P posterior, R right, L left
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posterior cingulate cortex/precuneus, and basal frontal
lobe. Our finding corresponded to Braak stage III–IV,
which is not consistent with previous neuropathological
and tau PET studies that tau pathology was usually lo-
calized in the MTL in the cognitively healthy partici-
pants [8, 9]. However, a recent large cohort study [10]
showed elevated 18F-THK5351 tau tracer retentions in
Braak stage III–IV areas with normal amyloid status and
raised the possibility of primary age-related tauopathy
(PART) [11]. Our results also support their results and
might reflect PART. PART is defined as NFT pathology
mostly restricted to the MTL, basal forebrain, brainstem,
and olfactory areas in the absence of β-amyloid in the
aged brain. Cognitive function is usually normal to
mildly impaired in PART, and severe cognitive decline is
rarely seen. Although PART is suggested to be an age-
related phenomenon distinct from early Alzheimer’s
disease, its pathophysiology is still unclear [1]. Thus,
further studies with tau PET are needed to better under-
stand the pathogenesis of PART.
The BPM analysis demonstrated a significant voxel-
wise negative correlation between 18F-THK5351 accu-
mulation and GM volume in the MTL, which was not
detected in the previous ROI-based analysis [5]. Al-
though ROI analysis is a common approach, it may not
be able to accurately assess localized accumulation due
to dilution effects. Because the BPM toolbox enables a
direct comparison across imaging modalities at the voxel
level, this voxel-based analysis may be more reliable than
traditional ROI-based analyses. Our findings are consist-
ent with neuropathological studies of PART patients
showing that a higher Braak NFT stage is associated
with hippocampal head atrophy [1]. Similar findings
have been reported in recent 18F-AV1451 tau PET stud-
ies, namely, that higher MTL tau is associated with MTL
atrophy [2]. Although they managed to obtain these re-
sults using a predefined FreeSurfer ROI approach, it is
possible that nonspecific 18F-AV1451 accumulation in
the choroid plexus adjacent to the MTL may not have
been eliminated.
This study has several limitations. First, the number of
participants was relatively small. Second, the study
lacked pathologic confirmation of tau pathology. Third,
the high affinity of 18F-THK5351 to MAO-B [3, 4] may
contribute to the relatively higher Braak stage of our
findings compared to PART type pathology which is
usually III or lower [11]. MAO-B concentration in-
creases during ongoing astrogliosis, which is considered
as neuroinflammation changes that occur in response to
brain injury and neurodegenerative disease [12]. Previ-
ous PET study in healthy subjects reported global MAO-
B increases in the whole brain even with human aging
[13], and the astrocytes seem to contribute to low-grade
inflammation in the aged brain [14]. Because 18F-
THK5351 uptake reflects the combination of astrogliosis
and tau pathology, the degree and extent of tracer reten-
tion could be higher than that of only tau pathology.
Recently, it is reported that aggregation of misfolded
proteins including TDP-43 and α-synuclein in addition
to Aβ and NFTs observed in PART are common even in
cognitively healthy elderly brain [15]. Since the mixed
pathologies are frequently observed in the aged brain,
they could evoke neuroinflammation and increase astro-
gliosis, resulting in accumulation of 18F-THK5351. The
early phase of age-related TDP-43 accumulation, known
as “limbic-predominant age-related TDP-43 encephalop-
athy (LATE),” which tends to extend to limbic areas
including the amygdala, could be part of the reasons
[16]. In addition, the stereological cell counting studies
showed declining of neocortical neuronal populations
but no changes of the total astrocyte numbers in the
aged human brains [17]. Therefore, the numbers of
astrocytes would tend to concentrate in the atrophied
MTL regions, suggesting the contribution of MAO-B in
addition to tau pathology.
In summary, we found significant voxel-wise nega-
tive correlations between 18F-THK5351 accumulation
and GM volume in the MTL. These results may re-
flect the concept of PART and contribute to a better
understanding of the neurobiology of aging. Further
studies are needed to confirm whether our findings
reflect PART pathology or not by taking an oral dose
of MAO-B inhibitor selegiline [3] or using second-
generation tau-specific tracers with much less off-tar-
get binding.
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